129 related articles for article (PubMed ID: 8064736)
1. Multicenter clinical trial of zinc acexamate in the prevention of nonsteroidal antiinflammatory drug induced gastroenteropathy. Spanish Study Group on NSAID Induced Gastroenteropathy Prevention.
Rodríguez de la Serna A; Díaz-Rubio M
J Rheumatol; 1994 May; 21(5):927-33. PubMed ID: 8064736
[TBL] [Abstract][Full Text] [Related]
2. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study.
Bianchi Porro G; Lazzaroni M; Petrillo M; Manzionna G; Montrone F; Caruso I
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):43-7. PubMed ID: 9615264
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
[TBL] [Abstract][Full Text] [Related]
4. [Endoscopic, histologic and morphometric evaluation of the gastric mucosa in patients with osteoarthritis treated with piroxicam and zinc acexamate].
Guilarte López-Mañas J; Valenzuela Barranco M; Caballero Plasencia AM; Martín Ruiz JL
Gastroenterol Hepatol; 1998 May; 21(5):212-7. PubMed ID: 9644873
[TBL] [Abstract][Full Text] [Related]
5. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial.
de Leest HT; Steen KS; Lems WF; Bijlsma JW; van de Laar MA; Huisman AM; Vonkeman HE; Houben HH; Kadir SW; Kostense PJ; van Tulder MW; Kuipers EJ; Boers M; Dijkmans BA
Helicobacter; 2007 Oct; 12(5):477-85. PubMed ID: 17760715
[TBL] [Abstract][Full Text] [Related]
6. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
Taha AS; Hudson N; Hawkey CJ; Swannell AJ; Trye PN; Cottrell J; Mann SG; Simon TJ; Sturrock RD; Russell RI
N Engl J Med; 1996 May; 334(22):1435-9. PubMed ID: 8618582
[TBL] [Abstract][Full Text] [Related]
7. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients.
Miglioli M; Bianchi Porro G; Vaira D; Menegatti M; Brunetti G; Petrillo M; Ardizzone S; Frizziero L; Montrone F; Grandinetti G
Am J Gastroenterol; 1996 Nov; 91(11):2367-71. PubMed ID: 8931419
[TBL] [Abstract][Full Text] [Related]
8. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
9. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
10. [Misoprostol in the prevention of gastric erosions caused by nonsteroidal anti-inflammatory agents].
Delmas PD; Lambert R; Capron MH
Rev Rhum Ed Fr; 1994 Feb; 61(2):126-31. PubMed ID: 7920500
[TBL] [Abstract][Full Text] [Related]
11. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
Bianchi Porro G; Lazzaroni M; Petrillo M
Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
[TBL] [Abstract][Full Text] [Related]
12. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
13. [Development and relapse of gastroduodenal ulcer in patients taking nonsteroid anti-inflammatory drugs: effects of standard risk factors].
Karateev AE; Nasonova VA
Ter Arkh; 2008; 80(5):62-6. PubMed ID: 18590118
[TBL] [Abstract][Full Text] [Related]
14. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study.
Raskin JB; White RH; Jaszewski R; Korsten MA; Schubert TT; Fort JG
Am J Gastroenterol; 1996 Feb; 91(2):223-7. PubMed ID: 8607484
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of misoprostol in the prophylaxis of gastroduodenal lesions induced by short-term nonsteroidal antiinflammatory drug therapy in elderly patients. A multicenter double-blind, placebo-controlled trial.
Piette F; Teillet L; Naudin R; Boichut D; Capron MH
Rev Rhum Engl Ed; 1997 Apr; 64(4):259-66. PubMed ID: 9178399
[TBL] [Abstract][Full Text] [Related]
16. Zinc compounds, a new treatment in peptic ulcer.
Escolar G; Bulbena O
Drugs Exp Clin Res; 1989; 15(2):83-9. PubMed ID: 2661183
[TBL] [Abstract][Full Text] [Related]
17. [Ranitidine in the treatment of non-steroidal anti-inflammatory agent-induced damage of the stomach and duodenal mucosa. Results of a randomized, placebo-controlled double-blind study in patients with rheumatic diseases].
Simon B; Beckers KH; Biewer W; Bouzo MH; Dammann HG; Gebest HJ; Müller P; Schütz E
Z Gastroenterol; 1988 Jun; 26(6):310-3. PubMed ID: 3061183
[TBL] [Abstract][Full Text] [Related]
18. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs.
Levine LR; Cloud ML; Enas NH
Arch Intern Med; 1993 Nov; 153(21):2449-54. PubMed ID: 8215749
[TBL] [Abstract][Full Text] [Related]
19. [A multicenter clinical trial. Zinc acexamate versus famotidine in the treatment of acute duodenal ulcer. Study Group of Zinc acexamate (new UP doses)].
García-Plaza A; Arenas JI; Belda O; Diago A; Domínguez A; Fernández C; Martín L; Pallarés A; Rodrigo L; de la Santa Jw
Rev Esp Enferm Dig; 1996 Nov; 88(11):757-62. PubMed ID: 9004781
[TBL] [Abstract][Full Text] [Related]
20. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
